Analysis of amino-terminal variants of amyloid-β peptides by capillary isoelectric focusing immunoassay.

Here we present a novel assay for the separation and detection of amino-terminal amyloid-β (Aβ) peptide variants by capillary isoelectric focusing (CIEF) immunoassay. Specific amino-terminally truncated Aβ peptides appear to be generated by β-secretase (BACE1)-independent mechanisms and have previously been observed in cerebrospinal fluid (CSF) after BACE1 inhibitor treatment in an animal model. CIEF immunoassay sensitivity is sufficient to detect total Aβ in CSF without preconcentration. To analyze low-abundance amino-terminally truncated Aβ peptides from cell culture supernatants, we developed a CIEF-compatible immunoprecipitation protocol, allowing for selective elution of Aβ peptides with very low background. CIEF immunoassay and immunoprecipitation mass spectrometry analysis identified peptides starting at residue Arg(5) as the main amino-terminal Aβ variants produced in the presence of tripartite BACE1 inhibitor in our cell culture model. The CIEF immunoassay allows for robust relative quantification of Aβ peptide patterns in biological samples. To assess the future possibility of absolute quantification, we have prepared the Aβ peptides Aβ(x-10), Aβ(x-16), and Aβ(5-38(D23S)) by using solid phase peptide synthesis as internal standards for the CIEF immunoassay.

[1]  J. Wiltfang,et al.  Optimisation of BACE1 inhibition of tripartite structures by modification of membrane anchors, spacers and pharmacophores - development of potential agents for the treatment of Alzheimer's disease. , 2012, Organic & biomolecular chemistry.

[2]  Kevin Mills,et al.  Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42. , 2012, Biomarkers in medicine.

[3]  H. Rosenmann.  CSF Biomarkers for Amyloid and Tau Pathology in Alzheimer's Disease , 2012, Journal of Molecular Neuroscience.

[4]  Erin E. Chambers,et al.  Quantitation of amyloid beta peptides Aβ(1-38), Aβ(1-40), and Aβ(1-42) in human cerebrospinal fluid by ultra-performance liquid chromatography-tandem mass spectrometry. , 2011, Analytical biochemistry.

[5]  J. Wiltfang,et al.  β-Amyloid Peptide Variants in Brains and Cerebrospinal Fluid from Amyloid Precursor Protein (APP) Transgenic Mice , 2011, The Journal of Biological Chemistry.

[6]  J. Wiltfang,et al.  Structural design, solid-phase synthesis and activity of membrane-anchored β-secretase inhibitors on Aβ generation from wild-type and Swedish-mutant APP. , 2010, Chemistry.

[7]  E. Mandelkow,et al.  Aβ Oligomers Cause Localized Ca2+ Elevation, Missorting of Endogenous Tau into Dendrites, Tau Phosphorylation, and Destruction of Microtubules and Spines , 2010, The Journal of Neuroscience.

[8]  G. Multhaup,et al.  Aberrant Amyloid Precursor Protein (APP) Processing in Hereditary Forms of Alzheimer Disease Caused by APP Familial Alzheimer Disease Mutations Can Be Rescued by Mutations in the APP GxxxG Motif* , 2010, The Journal of Biological Chemistry.

[9]  Shaomin Li,et al.  Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory , 2008, Nature Medicine.

[10]  J. Schulz,et al.  Efficient Inhibition of the Alzheimer's Disease β-Secretase by Membrane Targeting , 2008, Science.

[11]  P. Lewczuk,et al.  Urea‐based two‐dimensional electrophoresis of beta‐amyloid peptides in human plasma: Evidence for novel Aβ species , 2007, Proteomics.

[12]  Bernardo L Sabatini,et al.  Natural Oligomers of the Alzheimer Amyloid-β Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway , 2007, The Journal of Neuroscience.

[13]  O. Jahn,et al.  Technical innovations for the automated identification of gel-separated proteins by MALDI-TOF mass spectrometry , 2006, Analytical and bioanalytical chemistry.

[14]  Henrik Zetterberg,et al.  Determination of β-Amyloid Peptide Signatures in Cerebrospinal Fluid Using Immunoprecipitation-Mass Spectrometry , 2006 .

[15]  Anders Wallin,et al.  Amino-Truncated β-Amyloid42 Peptides in Cerebrospinal Fluid and Prediction of Progression of Mild Cognitive Impairment , 2005 .

[16]  P. Lewczuk,et al.  Electrophoretic separation of amyloid β peptides in plasma , 2004 .

[17]  T. Tabira,et al.  Amino‐truncated amyloid β‐peptide (Aβ5‐40/42) produced from caspase‐cleaved amyloid precursor protein is deposited in Alzheimer’s disease brain , 2004 .

[18]  A. Delacourte,et al.  Truncated beta‐amyloid peptide species in pre‐clinical Alzheimer's disease as new targets for the vaccination approach , 2003, Journal of neurochemistry.

[19]  J. Kornhuber,et al.  Highly conserved and disease‐specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation , 2002, Journal of neurochemistry.

[20]  M. Emmerling,et al.  Isolation, chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. , 1997, Biochemical and biophysical research communications.

[21]  D. Mann,et al.  Dominant and differential deposition of distinct β-amyloid peptide species, Aβ N3(pE), in senile plaques , 1995, Neuron.

[22]  G. Glenner,et al.  Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein , 1984 .